

21<sup>st</sup> December 00

STRICTLY PRIVATE & CONFIDENTIAL

To Whom It May Concern:

Re: Product manufactured from a plasma pool which includes  
a donation from a donor now diagnosed with vCJD

1. 18.12.2000.

Chief MLSO from the Blood Bank, Royal Victoria Hospital, informs me that a letter, addressed to her from BPL (Bio Products Laboratory) has been received, which indicates that BPL has now received notification that a UK donor has been diagnosed as suffering from variant Creutzfeldt-Jacob disease (vCJD) and plasma from the donor was supplied to BPL in 1996 and 1997. The affected batches of antithrombin III supplied were given as ATIII ATA 4535.

This information was verbally relayed to Mr Wilbur McDonald, Senior Chief MLSO, in order to set up a retrospective analysis of patients who have received this batch of antithrombin III.

2. 20.12.2000.

On 20<sup>th</sup> December 2000 my research registrar, Dr McNulty and I looked back manually at our annual returns to the UKHCDO in 1996, 1997 and 1998. We have identified the following patients as recipients of this batch of antithrombin III concentrate, although it is recognised that other patients within Northern Ireland may also have received this antithrombin III batch:-

- ✓ 1. A GRO-A 00691117 A
- ✓ 2. B GRO-A 82012561
- 3. C GRO-A 93020343
- ✓ 4. D GRO-A 60805408
- 5. E GRO-A 83003312
- 6. F GRO-A 00892004
- 7. G GRO-A 95002206
- ✓ 8. H GRO-A 00691117
- 9. I GRO-A AH131219

2031